NCT02723630View on ClinicalTrials.gov

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

Lenvatinib 10 mg

"Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%"

Trial Locations (1)

Unknown

Las Vegas

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02723630 - Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers | Biotech Hunter | Biotech Hunter